














Cite this: *Food Funct.*, 2025, 16, 3542

Suppression of fecal phenol production by oral supplementation of sesamol: inhibition of tyrosine phenol-lyase by sesamol†

Daiki Oikawa, ^{a,b} Zion Byun, ^b Bunzo Mikami, ^{c,d} Aina Gotoh, ^b Toshihiko Katoh, ^b Ryo Ueno,^b Aruto Nakajima, ^b Satoshi Yamashita, ^e Wakako Ikeda-Ohtsubo, ^f Seiji Takahashi, ^a Toshiyuki Waki, ^a Koichi Kikuchi,^g Takaaki Abe, ^g Takane Katayama ^{*b} and Toru Nakayama ^{*a}

Phenol is produced from dietary L-tyrosine by the action of tyrosine phenol-lyase (TPL) of gut bacteria and contributes to various physiological disorders, including skin diseases, certain cancers, and kidney dysfunction. We found that oral supplementation of sesamol (36 or 180 $\mu\text{g mL}^{-1}$) *ad libitum* for 14 days in mice significantly suppressed fecal phenol production. Fecal microbiota structure analysis in sesamol-supplemented and control groups revealed that their overall microbiota structures were indistinguishable. To explain the sesamol-induced suppression of fecal phenol production, we characterized inhibition of bacterial TPL by sesamol *in vitro*. Sesamol specifically inhibited bacterial TPL in a mixed-type fashion (K_i , 135 μM), which was rationalized by computational docking studies using the crystal structure of *Pantoea agglomerans* TPL that was determined at 1.3 Å resolution. Sesamol was detected at 0–0.295 $\mu\text{mol g}^{-1}$ feces in the sesamol-supplemented group. Given the K_i value of sesamol for TPL inhibition, these levels may not have been sufficient to fully inhibit TPL and suppress fecal phenol production. Therefore, the observed suppression of fecal phenol production upon oral sesamol supplementation arose not solely from the inhibition of TPL by sesamol, but also potentially from the effects of metabolites derived from sesamol and the antioxidant activities of sesamol and related metabolites. Nevertheless, these findings highlight the potential for using sesamol to prevent physiological disorders associated with phenol production by the gut microbiota.

Received 3rd October 2024,
Accepted 5th April 2025

DOI: 10.1039/d4fo04839c

rsc.li/food-function

1. Introduction

Phenol is one of the microbial products metabolized from dietary L-tyrosine by gut bacteria.¹ Phenol produced by gut bacteria is related to some physiological disorders in humans. As produced phenol is absorbed in the gut and delivered *via* the bloodstream to the skin where it accumulates, it makes the skin dull and incompletely cornified in mouse models,² or it inhibits the differentiation of keratinocytes in female human skin.³ Phenol was also found to promote the exacerbation of skin cancer in a mouse model.⁴ In addition, *in vitro* studies showed that phenol decreases the viability of colonic epithelial cells in humans.⁵ Moreover, phenol produced by gut bacteria has been implicated in the onset of leukemia.⁶ In terms of other pathogenic effects, phenol also induces thrombocytopenia and defective platelet aggregation in patients with kidney dysfunction.⁷ In the liver, phenol absorbed from the gut is converted to phenyl sulfate, and its level was found to increase with the progression of diabetes in rats. Furthermore, albuminuria and podocyte damage in kidney cells were induced by its

^aDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, 6-6-11, Aza Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8579, Japan.

E-mail: toru.nakayama.e5@tohoku.ac.jp

^bDivision of Integrated Life Science, Graduate School of Biostudies, Kyoto University, Oiwake-cho, Kitashirakawa, Sakyo-ku, Kyoto 606-8502, Japan.

E-mail: katayama.takane.6s@kyoto-u.ac.jp

^cResearch Institute for Sustainable Humanosphere, Kyoto University, Uji, Kyoto 611-011, Japan

^dInstitute of Advanced Energy, Kyoto University, Uji, Kyoto 611-011, Japan

^eDepartment of Material Chemistry, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma, Kanazawa, Ishikawa 902-1192, Japan

^fFood and Feed Immunology Group, Laboratory of Animal Products Chemistry, Graduate School of Agricultural Science, Tohoku University, 468-1 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8572, Japan


^gDivision of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4fo04839c>



administration in experiments on diabetes models, which exacerbated kidney dysfunction.⁸

Phenol is produced from L-tyrosine by a gut bacterial enzyme, tyrosine phenol-lyase (TPL, eqn (1)).



The TPL-catalyzed reaction requires pyridoxal 5'-phosphate (PLP) as a coenzyme, which is widely used in many enzymatic reactions in the amino acid metabolic pathways, including transamination and α,β - and α,γ -eliminations.⁹ Inhibition of bacterial TPL would be a promising strategy to prevent and/or treat physiological disorders caused by phenol microbially produced in the gut. In fact, oral administration of 2-aza-L-tyrosine, a competitive inhibitor of TPL with a K_i value of 135 μM ,¹⁰ to diabetic mice not only decreased the level of phenyl sulfate in plasma and tissues but also suppressed albuminuria in the model.⁸

Sesame (*Sesamum indicum* L.) seed oil exerts nephroprotective effects and contributes to the prevention of diabetes-induced disease.^{11,12} However, its molecular mechanism remains to be clarified. Sesame seed oil contains lignan-related compounds, such as sesamol, sesamin, and sesamol (3,4-methylenedioxyphenol, Fig. 1), which reportedly benefit human health in a wide variety of ways.¹³ Among these compounds, sesamol, which is formed by the thermal hydrolysis of sesamol, is the only molecule with a phenolic group in its molecular structure and potentially mimics phenol and the phenolic moiety of L-tyrosine. Consistent with this, our preliminary results showed that sesamol indeed inhibits bacterial TPL,¹⁵ implying that it might contribute to the prevention and/or treatment of physiological disorders caused by phenol produced by gut microbiota.

In this study, to further address this issue, sesamol was orally supplemented to mice to assess its effects on fecal phenol production and microbiota structure. Detailed kinetic studies were also carried out to investigate the mode of TPL inhibition by sesamol. The X-ray crystal structure of TPL from *Pantoea agglomerans* (PaTPL) was then determined at 1.3 Å resolution, and using this structure a molecular docking study was performed to structurally rationalize the results of enzyme inhibition kinetics. The findings obtained in this study highlight the potential for using sesamol to prevent various physiological disorders caused by phenol production by the gut microbiota, including skin diseases, certain cancers, and kidney dysfunction.




Fig. 1 Chemical structure of sesamol.

2. Materials and methods

2.1. Chemicals

(+)-Sesamin, sesaminol, and sesamol of $\geq 99\%$ purity were purchased from Nagara Science (Gifu, Japan). 2-O-(β -D-Glucopyranosyl)- β -D-glucopyranosylsesaminol [SDG(β 1-2)] and 6-O-(β -D-glucopyranosyl)- β -D-glucopyranosylsesaminol [SDG(β 1-6)] were prepared as described previously.¹⁶ Rabbit muscle L-lactate dehydrogenase (LDH) was obtained from Sigma-Aldrich (St Louis, MO, USA), while pig heart malate dehydrogenase (MDH) was obtained from Wako (Sendai, Japan). All other chemicals were of analytical grade.

2.2. Bacterial strains

The following bacterial strains were obtained from Riken BioResource Research Center (Tsukuba, Japan): *Clostridium cochlearium* JCM 1396^T, *Citrobacter freundii* JCM 1657^T, *Citrobacter koseri* JCM 1658^T, *Kluyvera intermedia* JCM 1238^T, *Lacrimispora sphenoides* JCM 1415^T, and *Morganella morganii* JCM 1672^T.

2.3. Animal experiments

C57BL/6N male mice of 8 weeks of age were obtained from SHIMIZU Laboratory Supplies Co., Ltd (Kyoto, Japan). The mice were co-housed in four polycarbonate cages under standard conditions [22 °C, 12 h light/dark cycle (lights on from 8 a.m. to 8 p.m.)], and randomly exchanged between the cages every day during a 7-day acclimation period. Food (MF; Oriental Yeast Co., Ltd, Tokyo, Japan) and water were available *ad libitum*. The mice were randomly assigned to three groups: C, L, and H. Group C served as the control, while Group L received a low dose of sesamol (36 $\mu\text{g mL}^{-1}$ in water) and Group H received a high dose of sesamol (180 $\mu\text{g mL}^{-1}$ in water). Each group consisted of seven mice ($n = 7$), which were housed individually. Body weight was measured as an indicator of food intake and health. Fecal pellets were collected from each mouse on Days 0, 7, and 14 within 6 h of defecation and stored at -30 °C until use. The fecal samples were weighed and transferred to a 2 mL plastic tube containing stainless-steel beads ($\varphi = 5.0$ mm), zirconia beads ($\varphi = 0.1$ mm, equivalent to 100 μL volume), and 5 volumes of 50% ethanol. The tubes were shaken at 1500 rpm for 10 min using a Shake Master Neo (Bio Medical Science, Tokyo, Japan), and the supernatant was collected after centrifugation. The pellets were suspended again with 50% ethanol and similarly shaken. The supernatants were combined, filtered through a 0.45 μm filter (Millipore), and subjected to the quantification of phenol and sesamol using a liquid chromatography–mass spectrometry (LC-MS) system. Animal experiments were approved by Kyoto University Animal Experimentation Committee (Lif-K24009) and performed in December 2024.

2.4. Microbiota analysis

Extraction of mouse fecal DNA and subsequent 16S rRNA gene-based microbiota analysis were conducted as described previously with slight modifications.¹⁷ In brief, lyophilized



fecal pellets were suspended in 300 μL of InhibitEX buffer appended to a QIAmpFast DNA Stool Mini Kit (Qiagen, Hilden, Germany), disrupted by bead-beating with a Shake Master NEO (Bio Medical Science, Tokyo, Japan), and the supernatants were collected by centrifugation. The following DNA extraction procedures were performed in accordance with the protocol provided with the kit. The V3–V4 region was amplified using a two-step PCR approach, in which KOD FX Neo (Toyobo, Osaka, Japan) was used for the first and second PCR. The sequencing was performed using a MiSeq instrument with MiSeq Reagent kit v3 (Illumina, San Diego, CA, USA). The primer sequences were trimmed with FastX_trimmer (FASTX-Toolkit, version 0.0.14), and low-quality reads (quality value <20, length <130 bp) were removed by Sickle (version 1.33). The paired-end sequences were assembled using FLASH (version 1.2.11). The reads were analyzed using the QIIME2 software package (version 2024.10). Potential chimeric sequences were removed using DADA2.¹⁸ Taxonomic classification was performed using a Naive Bayes classifier trained on the Greengenes 13.8 database clustered at the 97% identity threshold. Linear discriminant analysis (LDA) effect size (LEfSe) was used to determine the taxa that most strongly discriminated between different groups.¹⁹ Principal coordinate analysis (PCoA) was conducted based on Bray–Curtis distances, for which the vegan package in R (version 4.1.0) was used. The 16S rRNA amplicon sequencing data have been deposited in the DNA Data Bank of Japan under BioProject ID number PRJDB16730.

2.5. Enzyme preparation

Human alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were heterologously expressed in *Escherichia coli* cells, as described previously,¹⁵ and the cell-free extracts were used for enzyme assays. *PaTPL*²⁰ was heterologously expressed in *E. coli* cells and purified as described previously.¹⁵

2.6. Inhibition of phenol production of gut bacteria encoding TPL-homolog by sesamol

Overnight cultures of the strains described above in Gifu Anaerobic Medium (GAM; Nissui Pharmaceutical, Tokyo, Japan) were separately transferred to fresh EC-GY medium [GAM without added sugars (Nissui Pharmaceutical) supplemented with 1% (w/v) glycerol and 0.1% (w/v) L-tyrosine] at 1/100 dilution, and the cultivation was continued anoxically at 37 °C for 24 h. The cells were harvested and disrupted by ultrasonication, followed by centrifugation. The reaction mixture (final volume, 100 μL) contained 100 mM potassium phosphate buffer (pH 8.0), 100 μM PLP, 2 mM 2-mercaptoethanol (2-ME), 1 mM L-tyrosine, 1–25 μkat of enzyme, and 500 μM sesamol. The mixture was pre-incubated at 37 °C for 10 min in the absence of the enzyme, and the reaction was initiated by enzyme addition. After incubation at 37 °C for 30 min, the reaction was stopped by adding 100 μL of 4% (v/v) trifluoroacetic acid in a 4:6 (v/v) mixture of acetonitrile and water. After centrifugation, the amount of phenol in the supernatant was quantified by high-performance liquid chromatography (HPLC).

2.7. Effects of sesamol on activities of mammalian PLP- and NADH-dependent enzymes

ALT, AST, LDH, and MDH activities were assayed as described previously.^{21,22} Enzyme activities were measured in the presence of different concentrations (*i.e.*, 0, 20, 50, or 100 μM) of sesamol.

2.8. Effects of sesamol on viability of some gut bacteria

Overnight culture of bacteria (*C. koseri*, *L. sphenoides*, and *M. morgani*) in GAM medium was separately transferred to fresh EC-GY medium at 1/100 dilution, and the cultivation was continued anoxically at 37 °C for 24 h. The cells were harvested and suspended in an appropriate volume of a mixture containing 100 mM potassium phosphate buffer (pH 8.0), 200 μM PLP, and 1 mM 2-ME, to which 5 mM sesamol was added when necessary. The resulting cell suspensions, equivalent to OD₆₀₀ of 2.0, were anaerobically incubated in the presence or absence of 0.1% L-tyrosine at 37 °C for 24 h. The cells were harvested and suspended in 0.85% NaCl at serial dilutions, 100 μL of which was plated on GAM agar plates to estimate colony-forming units (CFU) per mL of the cell suspension.

2.9. Enzyme kinetics

The reaction mixture (final volume, 100 μL) contained 100 mM potassium phosphate buffer (pH 8.0), 100 μM PLP, 2 mM 2-ME, varying concentrations of L-tyrosine, 1–25 $\mu\text{kat mL}^{-1}$ *PaTPL*, and 15 μM sesamol or other sesame-derived compounds. The mixture was pre-incubated at 37 °C for 10 min in the absence of the enzyme, and the reaction was initiated by adding *PaTPL*. After incubation at 37 °C for 10 min, the reaction was stopped by adding 100 μL of 4% (v/v) trifluoroacetic acid in a 4:6 (v/v) mixture of acetonitrile and water. After centrifugation, the amount of phenol in the supernatant was quantified by HPLC, as described below. The inhibition mode was determined using double-reciprocal plots. Inhibition constants were determined by fitting the data to the Michaelis–Menten equation with competitive or mixed-type inhibition mode (eqn (2) or (3), respectively) using SigmaPlot (HULINKS, Tokyo, Japan).

$$v = \frac{V_{\max}[S]}{K_m \left(1 + \frac{[I]}{K_i} \right) + [S]} \quad (2)$$

$$v = \frac{V_{\max}[S]}{K_m \left(1 + \frac{[I]}{K_i} \right) + [S] \left(1 + \frac{[I]}{\alpha K_i} \right)} \quad (3)$$

Here, v and V_{\max} denote initial and maximum velocities of enzymatic reaction, $[S]$ and $[I]$ denote concentrations of substrate (S) and inhibitor (I), and K_m and K_i denote the Michaelis constant for S and the inhibition constant for I, respectively. α refers to the degree to which the binding of inhibitor changes the affinity of the enzyme for the substrate.

2.10. X-ray crystallographic studies of *PaTPL*

A tryptophanase-deficient *E. coli* JM101 strain transformed with a pUC-derived plasmid carrying the *PaTPL* gene²⁰ was



grown at 30 °C for 24 h in 500 mL of LB medium supplemented with 0.1% (w/v) L-tyrosine as an inducer. After cultivation, cells were harvested and disrupted by sonication. The cell-free extracts were subjected to 30% saturation of ammonium sulfate. Ammonium sulfate was added to the supernatant to 70% saturation, and the resulting precipitate was recovered by centrifugation. The pellet was dissolved in 3 mL of 20 mM potassium phosphate buffer (pH 8.0) containing 200 μ M PLP, 2 mM 2-ME, and 1 mM EDTA (pH 8.0), and the protein was concentrated using an Amicon Ultra-4 (10 K) centrifugal filter device (Merck Millipore, Burlington, MA, USA). The protein was then loaded onto a MonoQ 5/50 GL column (GE Healthcare, Tokyo, Japan) pre-equilibrated with the same buffer and eluted by a linear gradient of 0–1 M NaCl. The enzyme was further purified by SOURCE 15PHE column chromatography (GE Healthcare), in which the elution was carried out by a linear gradient of 1–0 M ammonium sulfate. The protein fractions with high purity were collected, concentrated by ammonium sulfate precipitation, and dialyzed against a crystallization solution consisting of 10 mM KCl, 200 μ M PLP, 4 mM 2-ME, and 1 mM EDTA using Slide-A-Lyzer G2 dialysis cassettes (10 K; Thermo Fisher Scientific, Tokyo, Japan). The purified enzyme was stored at –80 °C.

Crystals of PaTPL were grown at 20 °C using the hanging-drop vapor-diffusion method, by mixing 1 μ L of the protein solution with an equal volume of reservoir solution consisting of 0.2 M ammonium acetate (pH 7.5), 0.1 M sodium dihydrogen citrate (pH 4.2), 0.12 M sodium hydroxide, and 21% (v/v) PEG 4000. The crystals were flash-cooled in the cold nitrogen gas stream. Diffraction data were collected at 100 K at beamline BL26B1 of SPring-8 (Harima, Japan). The data sets were processed using X-ray Detector Software.²³ The structure was refined with PHENIX-refine²⁴ using the TPL model (PDB code, 1C7G) as an initial model. Model building was performed using COOT.²⁵ Molecular graphic images were prepared using PyMOL (version 2.5.4) (Schrödinger, NY, USA) or UCSF Chimera version 1.17.1 (Resource for Biocomputing, Visualization and Informatics, CA, USA). DALI server (<https://ekhidna.biocenter.helsinki.fi/dali>) was used for structural comparison between PaTPL and CfTPL (PDB code, 6DUR).²⁶

2.11. Molecular docking analysis

Computational docking simulations were performed through the SwissDock server program (<https://www.swissdock.ch/>)²⁷ using the crystal structures of a holo-enzyme of PaTPL (this study; PDB code, 7FJK) and a phenylalanine-bound form of CfTPL (PDB code, 6DUR). A search for binding sites of sesamol was performed in the 15 \times 15 \times 15 Å cube around the PLP-binding (Lys257) residue of TPL. Based on the obtained results, representative models with estimated ΔG values more negative than –5.2 kcal mol^{–1} were selected. Models in which the ligand clashed with the protein surface of PaTPL and CfTPL were excluded.

2.12. HPLC and LC-MS

Phenol and sesamol were quantified by either HPLC or LC-MS. For HPLC, a Shimadzu Prominence system (Shimadzu, Kyoto,

Japan) equipped with a photodiode array detector (model SPD M-20A; Shimadzu) and a J'sphere ODS-H80 column (4.6 \times 150 mm; YMC, Kyoto, Japan) was used. For the detection of phenol, elution was carried out at a flow rate of 0.7 mL min^{–1} with a linear gradient between solvent A [0.1% (v/v) trifluoroacetic acid in water] and solvent B [0.1% trifluoroacetic acid (v/v) in a 9 : 1 (v/v) mixture of acetonitrile and water]. The gradient system consisted of 20% B for 0–3 min, 20%–80% B for 3–11 min, 100% B for 11–14 min, and 20% B for 14–19 min. Column temperature was maintained at 25 °C, and the run was monitored by the absorbance at 280 nm. For the detection of sesamol, elution was started with 40% B for 3 min, followed by a linear gradient of 40%–65% B for 8 min, 100% B for 3 min, and 40% B for 5 min. The other conditions were the same as used for the phenol detection.

LC-MS was also used for the detection of phenol and sesamol. For the detection of phenol, a Shimadzu LC-MS8030 system with an Agilent 1260 Infinity II LC equipped with an InertSustain C18 HP column (3 μ m, 2.1 \times 100 mm; GL Sciences, Tokyo, Japan) was used. Elution was carried out at a flow rate of 0.25 mL min^{–1} with a linear gradient of 40%–90% (v/v) methanol in water in 8 min, and the eluate was ionized by atmospheric-pressure chemical ionization with negative mode. Data acquisition for phenol was performed in the Q1 selected ion monitoring mode at *m/z* 93. For the detection of sesamol, the same LC-MS system was used. The elution was carried out at a flow rate of 0.3 mL min^{–1} with a linear gradient of 20%–30% (v/v) methanol in water in 9 min. An electrospray interface was used in negative mode. Data acquisition was performed in the Q1 selected ion monitoring mode at *m/z* 137.12. For both HPLC and LC-MS, the known concentrations of phenol and sesamol were used to produce standard curves.

2.13. Statistics

Data are shown as mean \pm standard deviation (SD) or median with interquartile range. Statistical analysis was performed using GraphPad Prism version 10.4.1 (GraphPad Software Inc., San Diego, CA, USA). *P* values of less than 0.05 were considered statistically significant.

3. Results

3.1. Effect of sesamol supplementation on fecal phenol production in mice

Acclimated 9-week-old C57BL/6N male mice were randomly assigned to three groups (Groups C, L, and H; *n* = 7 per group) and housed in parallel for 14 days with *ad libitum* access to food and water. The low-dose sesamol-supplemented group (Group L) received water containing 36 μ g mL^{–1} sesamol, while the high-dose group (Group H) received water with a sesamol concentration five times higher (180 μ g mL^{–1}). The control group (Group C) received water without sesamol. Note that the dose of sesamol for Group L was determined on the basis of our previous study,⁸ in which 2-aza-L-tyrosine, a competitive inhibitor of TPL, was orally administered to a mouse at



0.3 mg a day. During the course of the experiment, there were no sudden deaths, loss of appetite, or immobility among the mice used, and thus no mice were excluded. No significant differences were found among the three groups in terms of body weight on Days 0, 7, and 14 (Fig. 2A). Fecal samples were collected from the seven individuals in each of Groups C, L, and H on Days 0, 7, and 14 after supplementation. This resulted in seven fecal samples for each of nine conditions: C0, C7, C14, L0, L7, L14, H0, H7, and H14 (where, for example, C0 represents Group C on Day 0). The phenol content of these samples was measured using LC-MS. The phenol concentrations in fecal samples were 0.0230 ± 0.0095 , 0.0092 ± 0.0060 , and $0.0069 \pm 0.0032 \mu\text{mol g}^{-1}$ feces for Groups C7, L7, and H7, and 0.0321 ± 0.0092 , 0.0140 ± 0.0066 , and $0.0087 \pm 0.0049 \mu\text{mol g}^{-1}$ feces for Groups C14, L14, and H14, respectively (Fig. 2B). The results indicated that the fecal phenol content in Group C mice increased during the intervention, whereas those in Groups L and H remained significantly lower than in Group C.

3.2. Effect of oral sesamol supplementation on fecal microbiota

Then, 16S rRNA gene-based fecal microbiota analysis was carried out with fecal samples of C0, C14, L0, L14, H0, and H14. We first analyzed the species richness (α -diversity) in the microbial communities of the fecal samples from these six conditions by comparing the number of amplicon sequence variants (ASVs), which reflects taxonomic diversity. No significant difference in the number of ASVs was detected among these six conditions (Fig. 3A). We then analyzed the phylogenetic diversity (*i.e.*, the β -diversity) among the fecal microbiota

structures using PCoA based on Bray–Curtis dissimilarities. The PCoA matrices contained the dissimilarity in species composition between all combinations of subjects, which quantifies the phylogenetic β -diversity between groups; a group with a smaller Bray–Curtis dissimilarity value has lower phylogenetic variation (*i.e.*, smaller β -diversity) in its microbiota structure. In the results, the distributions of the plots of the seven fecal samples of the six conditions appeared to be essentially indistinguishable from each other (Fig. 3B), suggesting that the oral supplementation of sesamol did not cause a remarkable difference or shift in the microbiota structure of feces among Groups C, L, and H or within a single group over time. We also analyzed the fecal microbiota phylogenies of C0, C14, L0, L14, H0, and H14 at the phylum and genus levels (Fig. 3C). Because the relative abundances of certain phyla and genera appeared to vary slightly among the groups (Fig. 3C), we conducted LefSe analysis to statistically examine their differences among the samples in greater detail. The results showed no statistically significant variation in the relative abundance of any bacterial taxa among C0, L0, H0, C14, L14, and H14. When performing analysis using C14, L14, and H14 to assess the effects of sesamol supplementation, we found that *Staphylococcus* was the only genus that showed a significant decrease in abundance in L14 and H14 compared with that at C14 (Fig. 3D). However, because the fecal abundance of this taxon was originally very low, the size of this change was negligible. Overall, these findings suggest that the gut microbiota structures of mice of Groups C, L, and H remained largely unchanged after the 14-day intervention, indicating that sesamol supplementation had minimal impact on the structure of the gut microbiota in mice.

3.3. Enzymatic characterization of TPL inhibition by sesamol

In vitro studies were then conducted to assess the specificity of TPL inhibition by sesamol. Sesamol was found to inhibit the TPL activity of a wide range of gut bacteria, which had previously been shown to either accumulate high concentrations of phenol in culture supernatants or encode a TPL homolog^{28,29} (Fig. 4A; see also ESI Table S1†). However, it did not inhibit the activity of the following enzymes: ALT (EC 2.6.1.2) and AST (EC 2.6.1.1), which are PLP-dependent enzymes in humans, or LDH (EC 1.1.1.27, from rabbit muscle) and MDH (EC 1.1.1.37, from pig heart), which are NADH-dependent enzymes (Fig. 4B). Thus, sesamol exhibited high specificity toward bacterial TPL. Furthermore, sesamol did not affect bacterial cell viability (Fig. 4C), highlighting that its effects are limited to inhibiting gut bacterial metabolism involved in phenol production.

TPL inhibition by sesamol was then kinetically analyzed using *Pa*TPL. Double-reciprocal plots of the activity data in the presence and absence of sesamol (15 μM) intersect to the left of the $1/v$ -axis and above the $1/[S]$ -axis (Fig. 5A). These results indicate that the data exhibit the best fit to a mixed-type inhibition model (Fig. 5B), in which sesamol binds to E and ES to form catalytically inactive EI and ESI complexes, with a K_i value of 135 μM and α value of 1.57 (Fig. 5A, Table 1; see the




Fig. 2 Supplementation of sesamol in a mouse model and its effect on fecal phenol production. (A) Body weight of the mice orally supplemented with water or sesamol. (B) Fecal phenol production of the mice supplemented with water (Group C) or sesamol (Groups L and H) on Days 0 (left), 7 (center), and 14 (right). All data are expressed as the median ($n = 7$). Significance was assessed by the Kruskal–Wallis test.






Fig. 5 Kinetic analysis of *PaTPL* inhibition by sesamol. (A) Double-reciprocal plots of the *PaTPL*-catalyzed reaction in the presence (red) or absence (blue) of sesamol. The data are expressed as the mean \pm SD ($n = 3$). (B) Proposed model of *PaTPL* inhibition by sesamol. E, *PaTPL*; S, L-tyrosine; P, pyruvate, phenol, and ammonia; I, sesamol; ES, a Michaelis complex of *PaTPL* with L-tyrosine; EI, a complex of *PaTPL* with sesamol; ESI, a ternary complex of *PaTPL*, L-tyrosine, and sesamol. The α value refers to the degree to which the binding of sesamol changes the affinity of *PaTPL* for its substrate (L-tyrosine).

Table 1 Kinetic parameters of *PaTPL*

Inhibitor	K_i^α (μM)	α value for mixed-type inhibition	Inhibition type
2-Aza-L-tyrosine	71.5 ± 7.6	—	Competitive
(+)-Sesamin	77.9 ± 2.9	0.995	Mixed-type
Sesaminol	74.1 ± 2.3	6.89	Mixed-type
Sesamol	135 ± 67	1.57	Mixed-type
SDG(β 1-2)	264 ± 77	0.586	Mixed-type
SDG(β 1-6)	182 ± 54	0.208	Mixed-type

^a The values are presented as the average of three independent determinations with \pm SDs.

mean square deviation of 0.4 Å for 455 C α atoms (z -score = 67.0), as revealed by a Dali search (<https://ekhidna.biocenter.helsinki.fi/dali>) (see ESI Fig. S2† for further details of a comparison of the crystal structures of *PaTPL* and *CfTPL*). We also attempted to obtain crystal structures of *PaTPL* in complex with sesamol by co-crystallization and immersion experiments, but all attempts failed. Therefore, we performed a computational docking simulation by using SwissDock (<https://www.swissdock.ch/>). When sesamol was docked with the crystal structure of PLP-bound *PaTPL* (PDB code, 7FJK), the sesamol molecule was predicted to bind to the catalytic center of the enzyme (Fig. 6B, left). In the modeled structure, the methylenedioxy ring of the bound sesamol is located near Tyr71 of *PaTPL* (Fig. 6B, middle), which corresponds to the residue from the neighboring subunit in the catalytic dimer.³⁰ Moreover, a comparison of this structural model with the crystal structure (PDB code, 6DUR) of *CfTPL* complexed with L-phenylalanine, a competitive inhibitor of TPL, suggested that the bound sesamol is located where the phenyl moiety of the bound phenylalanine is accommodated in *CfTPL* (Fig. 6B, right). These docking results were consistent with the proposed inhibition model, where sesamol competes with




Fig. 6 The crystal structure of *PaTPL* and the predicted structures of sesamol–TPL complexes. (A) The crystal structure of *PaTPL* determined at 1.3 Å resolution (PDB code, 7FJK). The overall structure consists of four identical subunits, each of which is differently colored, and can be regarded as a “dimer of a dimer”. The subunits of one of these dimers (left) are shown in blue and sky blue, and those of the other dimer (right) are shown in magenta and red. Each of these dimers produces the active site in its monomer–monomer interface and conjugates at the N-terminus, resulting in the formation of a tetrameric structure. For further details of the characterization of the crystal structure of *PaTPL*, see ESI Fig. S2.† (B) Predicted structure of a binary *PaTPL*–sesamol complex. One of the results of docking simulations with the estimated ΔG values more negative than $-5.2 \text{ kcal mol}^{-1}$ is shown. Left, The structure of a dimer portion of *PaTPL* is shown using an overlaid ribbon and surface diagram, with catalytic Lys257 (blue), Tyr71 (dark gray), bound sesamol (yellow), and PLP (red) shown in a stick model. Middle, Magnified images showing the predicted location of the bound sesamol molecule in the catalytic site. Right, Superposition of the sesamol-bound model of *PaTPL* and L-phenylalanine molecule bound in the *CfTPL* structure (PDB code, 6DUR), in which overlapping monomer structures of *PaTPL* (PDB code, 7FJK) and *CfTPL* (PDB code, 6DUR) are shown using a ribbon model (*PaTPL*, dark gray; *CfTPL*, light gray). The positions of sesamol and the phenyl moiety of L-phenylalanine partially overlap. (C) Predicted structure of a ternary *CfTPL*–sesamol–L-phenylalanine complex. One of the representative models with estimated ΔG values more negative than $-5.2 \text{ kcal mol}^{-1}$ is shown. One of the top results of docking simulations is shown. Close-up image around the active site of *PaTPL* and *CfTPL* is also presented next to the overall structure with a stick model of catalytic residue Lys257 (*PaTPL*, blue; *CfTPL*, sky blue), Tyr71 in *PaTPL* (black), cofactor PLP (red), L-phenylalanine quinonoid complex binding to *CfTPL* (orange), and sesamol (yellow).

L-tyrosine for the active site of TPL (Fig. 5B, step i-1). We also examined the possible formation of an ESI complex (Fig. 5B, step i-2) by computational docking of sesamol with the L-phenylalanine-bound *CfTPL* structure (PDB code, 6DUR), which mimics the ES complex. It was predicted that sesamol binds to the entrance of the active-site cavity (Fig. 6C) of the binary complex to form ESI and inhibit product formation (Fig. 5B, step i-2). These docking results are consistent with the proposed model of TPL inhibition by sesamol based on our kinetic analysis (Fig. 5).

3.4. Determination of fecal sesamol content

Fecal sesamol contents of the mice in Groups L and H were measured on Days 0, 7, and 14. A low level of sesamol was found in almost all of the mice in both groups on Day 7 and Day 14, whereas no detectable level of sesamol could be found in each group on Day 0 (Table 3).



Table 2 Data collection and refinement statistics of PaTPL crystal

	TPL/citrate
A. Diffraction data	
X-ray source	SPring-8/BL26B1
Detector	Eiger4M
Wavelength (Å)	1.0
Resolution range (Å)	50.00–1.30 (1.37–1.30)
Space group	$P2_12_12$
Unit cell parameters	
a, b, c (Å)	111.62, 161.08, 100.15
Unique reflections	442 369 (70 556)
Multiplicity	4.17 (4.11)
Completeness (%)	99.6 (98.9)
Mean $I/\sigma(I)$	12.0 (2.6)
Wilson B -factor (Å ²)	19.1
R_{merge} (%)	6.3 (44.6)
R_{meas} (%)	7.3 (51.1)
$CC_{1/2}$ (%)	99.7 (85.6)
B. Refinement statistics	
Refinement program	Phenix 1.18.2
Resolution range used refinement	45.68–1.30 (1.31–1.30)
Number of reflections	442 342 (13 991)
R_{work} (%)	12.9 (24.7)
R_{free} (%)	15.5 (28.6)
Number of protein residues	456 (1–456) × 4 (chain A, B, C, D)
PLP/CIT/EOD/PEG/PGE/water	4/4/3/65/2/1/2040
R.m.s.d., bond lengths (Å)	0.005
R.m.s.d., bond angles (°)	0.86
Ramachandran favored (%)	98.1
Ramachandran outliers (%)	0
Rotamer outliers (%)	1.2
Clash score	5.3
PDB ID	7FJK

Table 3 Fecal sesamol content

Day	Group			
	L		H	
	Mouse no.	Sesamol content (μmol g ⁻¹ feces)	Mouse no.	Sesamol content (μmol g ⁻¹ feces)
0	1	<i>a</i>	1	<i>a</i>
	2	<i>a</i>	2	<i>a</i>
	3	<i>a</i>	3	<i>a</i>
	4	<i>a</i>	4	<i>a</i>
	5	<i>a</i>	5	<i>a</i>
	6	<i>a</i>	6	<i>a</i>
	7	<i>a</i>	7	<i>a</i>
7	1	<i>a</i>	1	0.025
	2	0.006	2	0.016
	3	0.014	3	0.027
	4	0.007	4	0.020
	5	0.011	5	0.034
	6	0.014	6	0.015
	7	<i>a</i>	7	0.014
14	1	0.042	1	0.234
	2	0.051	2	0.129
	3	0.041	3	0.023
	4	0.048	4	0.045
	5	0.026	5	0.074
	6	0.005	6	0.033
	7	0.026	7	0.295

^a Below detection limit (0.005 μmol g⁻¹ feces).

4. Discussion

A wide variety of human health benefits conferred by the bioactivities of sesamol have been reported,¹³ which include antioxidant,³¹ neuroprotective,³² cardioprotective,³³ anticancer,^{34,35} anti-inflammatory,³⁶ radioprotective,³⁷ and skin-protective effects.³⁸ In this study, we demonstrated in mice that oral supplementation of sesamol significantly suppressed phenol production in feces (Fig. 2B), while not causing significant changes in the gut microbiota structure (Fig. 3). These results provide evidence supporting an additional potential role of sesamol as a nutraceutical (a food chemical that provides health benefits in addition to its nutritional content), namely, for the prevention and treatment of physiological disorders caused by phenol produced by gut microbiota, including skin diseases, certain cancers, and kidney dysfunction.

A previous study using a mouse model showed that the oral administration of 2-aza-L-tyrosine also decreased phenol levels in feces and achieved a nephroprotective effect (*i.e.*, suppressing albuminuria).⁸ 2-Aza-L-tyrosine is a competitive inhibitor of TPL,¹⁰ and these observations have been ascribed to the fact that this amino acid derivative inhibits TPL of gut bacteria to suppress phenol production.⁸ Therefore, we further investigated the mechanistic aspects of the observed suppression of

fecal phenol production by sesamol. Results from the present TPL inhibition studies revealed that sesamol acts as an inhibitor of TPL irrespective of the microbial origin of the enzyme, without killing TPL-producing microbes (Fig. 4A and C). Our previous study showed that sesamol also acted as an inhibitor of bacterial tryptophan indole-lyase, which is responsible for the formation of indoxyl sulfate, a uremic toxin.¹⁵ For comparison, however, sesamol was shown not to inhibit human ALT, human AST, rabbit muscle LDH, and pig heart MDH (Fig. 4B). Therefore, enzyme inhibition by sesamol appears to be specific to PLP-dependent enzymes catalyzing the α,β -elimination of aromatic amino acids. Kinetic analysis indicated that sesamol acts as a mixed-type inhibitor of TPL, with a K_i value of 135 μM, which is comparable to the K_i of 2-aza-L-tyrosine [135 μM,¹⁰ 72 μM (this study; see Table 1)] known for its ability to decrease fecal phenol levels.⁸ The specific inhibition of TPL by sesamol was further supported by structural models of TPL–sesamol complexes. It was predicted that sesamol binds to the active site of TPL *via* its interaction with Tyr71 (Fig. 6B), which is functionally important for TPL catalysis.³⁰ It was also suggested that sesamol possibly binds near the active site of the TPL enzyme–substrate complex to inhibit catalytic reactions (Fig. 6C).

Sesamol was detected in the feces of nearly all mice in Groups L and H on Days 7 and 14. However, its concentrations were low. Given the K_i value of sesamol for TPL inhibition, these levels may not have been sufficient to fully inhibit TPL and suppress fecal phenol production. The low recovery of



orally administered sesamol in mouse feces is likely due to xenobiotic metabolism. In rats, sesamol undergoes hepatic metabolism, converting it into 2-methoxybenzene-1,4-diol, benzene-1,2,4-triol, and glucuronide or sulfate conjugates.^{39,40} Although sesamol metabolism in mice has not been extensively studied, similar metabolic pathways are likely present, reducing the proportion of orally supplemented sesamol that reaches the colon. Additionally, sesamol conjugates formed in the liver may be excreted into bile, transported to the colon, and subsequently deconjugated by microbial activity.⁴¹ Fecal sesamol concentrations may also be affected by water absorption in the colon. Variability in these processes and water intake from *ad libitum* administration could account for the sporadic detection of sesamol in certain mice (*e.g.*, mouse No. 1 and 7 in Group H). Thus, the observed reduction in fecal phenol production following oral sesamol supplementation was likely due not only to the direct inhibition of TPL by sesamol but also, at least in part, to unidentified effects of its metabolites generated through hepatic xenobiotic metabolism. Further research is needed to identify these metabolites and clarify their role in phenol suppression. Moreover, recent studies have suggested that the antioxidant properties of certain phenolic compounds can influence metabolic pathways independently of their effects on gut microbiota.⁴² Sesamol is known for its strong antioxidant activity,⁴³ which may modulate amino acid metabolism, particularly that of L-tyrosine. Additionally, oral administration of a diet containing sesaminol, a sesame-derived lignan with antioxidant properties, has been shown to increase tocopherol levels in the plasma and tissues of rats.⁴⁴ These findings suggest that the suppression of phenol production by sesamol in mice may involve similar indirect mechanisms.

A key challenge in the effective use of nutraceuticals for disease prevention and therapy is the limited understanding of their mechanisms of action, which underpins their efficacy.^{45,46} The identification of sesamol as a bacterial TPL inhibitor strongly suggests its potential as a mechanism-based agent⁴⁶ for both preventive and therapeutic strategies in addressing physiological disorders caused by phenol production from gut microbiota, including skin diseases, certain cancers, and kidney dysfunction. However, the bioavailability of sesamol—specifically, the proportion of ingested sesamol that reaches the target site (the gut) in its active form—must be taken into account. Only sesamol that reaches and is distributed to the gut can exert its beneficial health effects *via* TPL inhibition. To achieve this, several strategies could be explored. For example, the encapsulation of sesamol in enteric-coated capsules and its administration to deliver concentrations equivalent to its K_i in the colon should be investigated in future studies.

5. Conclusions

Oral supplementation of sesamol in mice significantly suppressed fecal phenol production with only a minimal effect on

the gut microbiota structure. Although sesamol specifically inhibited bacterial TPL activity, the suppression of fecal phenol production could be only partly attributed to TPL inhibition. Nevertheless, the findings from this study underscore the potential of using sesamol to prevent physiological disorders linked to phenol production by the gut microbiota, including skin diseases, certain cancers, and kidney dysfunction.

Abbreviations

2-ME	2-Mercaptoethanol
ALT	Alanine aminotransferase
AST	Aspartate transaminase
ASV	Amplicon sequence variant
HPLC	High-performance liquid chromatography
LC-MS	Liquid chromatography-mass spectrometry
LDA	Linear discriminant analysis
LDH	Lactate dehydrogenase
LEfSe	Linear discriminant analysis effect size
MDH	Malate dehydrogenase
NADH	Nicotinamide adenine dinucleotide reduced form
PLP	Pyridoxal 5'-phosphate
TPL	Tyrosine phenol-lyase

Author contributions

Daiki Oikawa: conceptualization, funding acquisition, investigation, data curation, validation, writing – original draft preparation. Zion Byun: investigation, data curation. Bunzo Mikami: conceptualization, investigation, data curation, validation, writing – reviewing and editing. Aina Gotoh: investigation, data curation. Toshihiko Katoh: investigation, data curation. Ryo Ueno: investigation. Aruto Nakajima: investigation. Satoshi Yamashita: methodology, data curation. Wakako Ikeda-Ohtsubo: investigation, data curation. Seiji Takahashi: investigation, data curation. Toshiyuki Waki: investigation, data curation. Koichi Kikuchi: investigation, data curation. Takaaki Abe: conceptualization, funding acquisition, supervision, project administration. Takane Katayama: conceptualization, funding acquisition, supervision, investigation, data curation, validation, project administration, writing – reviewing and editing. Toru Nakayama: conceptualization, funding acquisition, supervision, investigation, data curation, validation, project administration, writing – reviewing and editing.

Data availability

Coordinates and structure factors of the crystal structure of the PLP-bound holo-enzyme of *Pa*TPL have been deposited in the Protein Data Bank with accession code 7FJK. The 16S rRNA amplicon sequencing data have been deposited in the DNA Data Bank of Japan under BioProject ID number PRJDB16730. Data will be made available on request.



Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

Diffraction data were collected at the BL26B1 beamline of SPring-8, Sayo, Hyogo, Japan, with the approval of JASRI (proposal no. 2020A2744). This work was supported in part by a National Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (20K20604 and 21H02932 to TA, JP22J00724 to DO, and 23H05470 to TN), grants from the Japan Agency for Medical Research and Development (AMED) (22ek0120133, JP22ak010127, JP23fk0108655, and JP23zf127001 to TA), and a grant from Noda Institute for Scientific Research (to DO). We thank Edanz Group (<https://jp.edanz.com>) for editing a draft of this manuscript.

References

- 1 E. A. Smith and G. T. Macfarlane, Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine, *Microb. Ecol.*, 1997, **33**, 180–188.
- 2 R. Iizuka, K. Kawakami, N. Izawa and K. Chiba, Phenols produced by gut bacteria affect the skin in hairless mice, *Microb. Ecol. Health Dis.*, 2009, **21**, 50–56.
- 3 R. Iizuka, K. Kawakami and K. Chiba, Gut bacteria producing phenols disturb keratinocyte differentiation in human skin, *Microb. Ecol. Health Dis.*, 2009, **21**, 221–227.
- 4 R. K. Boutwell and D. K. Bosch, The tumor-promoting action of phenol and related compounds for mouse skin, *Cancer Res.*, 1959, **19**, 413–424.
- 5 K. Windey, V. De Preter and K. Verbeke, Relevance of protein fermentation to gut health, *Mol. Nutr. Food Res.*, 2012, **56**, 184–196.
- 6 T. A. McDonald, N. T. Holland, C. Skibola, P. Duramad and M. T. Smith, Hypothesis: phenol and hydroquinone derived mainly from diet and gastrointestinal flora activity are causal factors in leukemia, *Leukemia*, 2001, **15**, 10–20.
- 7 S. F. Rabiner and F. Molinas, The role of phenol and phenolic acids on the thrombocytopeny and defective platelet aggregation of patients with renal failure, *Am. J. Med.*, 1970, **49**, 346–351.
- 8 K. Kikuchi, D. Saigusa, Y. Kanemitsu, Y. Matsumoto, P. Thanai, N. Suzuki and T. Abe, Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease, *Nat. Commun.*, 2019, **10**, 1835.
- 9 R. S. Phillips, Chemistry and diversity of pyridoxal-5'-phosphate dependent enzymes, *Biochim. Biophys. Acta, Proteins Proteomics*, 2015, **1854**, 1167–1174.
- 10 E. B. Watkins and R. S. Phillips, Inhibition of tyrosine phenol-lyase from *Citrobacter freundii* by 2-azatyrosine and 3-azatyrosine, *Biochemistry*, 2001, **40**, 14862–14868.
- 11 D. Z. Hsu, Y. H. Li, P. Y. Chu, S. Periasamy and M. Y. Liu, Sesame oil prevents acute kidney injury induced by the synergistic action of aminoglycoside and iodinated contrast in rats, *Antimicrob. Agents Chemother.*, 2011, **55**, 2532–2536.
- 12 D. Sankar, A. Ali, G. Sambandam and R. Rao, Sesame oil exhibits synergistic effect with anti-diabetic medication in patients with type 2 diabetes mellitus, *Clin. Nutr.*, 2011, **30**, 351–358.
- 13 A. Shah, R. Lobo, N. Krishnadas and R. Surubhotla, Sesamol and health—a comprehensive review, *Indian J. Pharm. Educ. Res.*, 2019, **53**, S28–S42.
- 14 H. Yoshida and S. Takagi, Effects of seed roasting temperature and time on the quality characteristics of sesame (*Sesamum indicum*) oil, *J. Sci. Food Agric.*, 1997, **75**, 19–26.
- 15 D. Oikawa, S. Yamashita, S. Takahashi, T. Waki, K. Kikuchi, T. Abe and T. Nakayama, (+)-Sesamin, a sesame lignan, is a potent inhibitor of gut bacterial tryptophan indole-lyase that is a key enzyme in chronic kidney disease pathogenesis, *Biochem. Biophys. Res. Commun.*, 2022, **590**, 158–162.
- 16 A. Nair, A. Kuwahara, A. Nagase, H. Yamaguchi, T. Yamazaki, M. Hosoya, A. Omura, K. Kiyomoto, M. Yamaguchi, T. Shimoyama, S. Takahashi and T. Nakayama, Purification, gene cloning, and biochemical characterization of a β -glucosidase capable of hydrolyzing sesaminol triglucoside from *Paenibacillus* sp. KB0549, *PLoS One*, 2013, **8**, e60538.
- 17 T. Katoh, C. Yamada, M. D. Wallace, A. Yoshida, A. Gotoh, M. Arai, T. Maeshibu, T. Kashima, A. Hagenbeek, M. N. Ojima, H. Takada, M. Sakanaka, H. Shimizu, K. Nishiyama, H. Ashida, J. Hirose, M. Suarez-Diez, M. Nishiyama, I. Kimura, K. A. Stubbs, S. Fushinobu and T. Katayama, A bacterial sulfoglycosidase highlights mucin O-glycan breakdown in the gut ecosystem, *Nat. Chem. Biol.*, 2023, **19**, 778–789.
- 18 B. J. Callahan, P. J. McMurdie, M. J. Rosen, A. W. Han, A. J. A. Johnson and S. P. Holmes, DADA2: high-resolution sample inference from Illumina amplicon data, *Nat. Methods*, 2016, **13**, 581–583.
- 19 N. Segata, J. Izard, L. Waldron, D. Gevers, L. Miropolsky, W. S. Garrett and C. Huttenhower, Metagenomic biomarker discovery and explanation, *Genome Biol.*, 2011, **12**, R60.
- 20 T. Koyanagi, T. Katayama, A. Hirao, H. Suzuki and H. Kumagai, Construction of an effective protein expression system using the TPL promoter in *Escherichia coli*, *Biotechnol. Lett.*, 2005, **27**, 1267–1271.
- 21 H. U. Bergmeyer and E. Berndt, in *Methods of Enzymatic Analysis*, ed. H. U. Bergmeyer, Academic Press, New York, 2nd edn, 1974, pp. 574–579.
- 22 R. Rej, Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues, *Clin. Chem.*, 1978, **24**, 1971–1979.
- 23 W. Kabsch, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 125–132.
- 24 D. Liebschner, P. V. Afonine, M. L. Baker, G. Bunkoczi, V. B. Chen, T. I. Croll, B. Hintze, L.-W. Hung, S. Jain, A. J. McCoy, N. W. Moriarty, R. D. Oeffner, B. K. Poon,



- M. G. Prisant, R. J. Read, J. S. Richardson, D. C. Richardson, M. D. Sammito, O. V. Sobolev, D. H. Stockwell, T. C. Terwilliger, A. G. Urzhumtsev, L. L. Videau, C. J. Williams and P. D. Adams, Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix, *Acta Crystallogr., Sect. D: Struct. Biol.*, 2019, **75**, 861–877.
- 25 P. Emsley, B. Lohkamp, W. G. Scott and K. Cowtan, Features and development of Coot, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 486–501.
- 26 R. S. Phillips and S. Craig, Crystal structures of wild-type and F448A mutant *Citrobacter freundii*, tyrosine phenol-lyase complexed with a substrate and inhibitors: implications for the reaction mechanism, *Biochemistry*, 2018, **57**, 6166–6179.
- 27 A. Grosdidier, V. Zoete and O. Michielin, SwissDock, a protein-small molecule docking web service based on EADock DSS, *Nucleic Acids Res.*, 2011, **39**, W270–W277.
- 28 Y. Saito, T. Sato, K. Nomoto and H. Tsuji, Identification of phenol- and *p*-cresol-producing intestinal bacteria by using media supplemented with tyrosine and its metabolites, *FEMS Microbiol. Ecol.*, 2018, **94**, fiy125.
- 29 W. Yuan, S. Zhong, Y. Xiao, Z. Wang and J. Sun, Efficient biocatalyst of L-DOPA with *Escherichia coli* expressing a tyrosine phenol-lyase mutant from *Kluyvera intermedia*, *Appl. Biochem. Biotechnol.*, 2020, **190**, 1187–1200.
- 30 T. Katayama and H. Kumagai, Tyrosine Phenol-Lyase, in *Encyclopedia of Industrial Biotechnology*, ed. and M. C. Flickinger, John Wiley & Sons, 2010, pp. 4752–4757.
- 31 J. Lee and E. Choe, Extraction of lignan compounds from roasted sesame oil and their effects on the autoxidation of methyl linoleate, *J. Food Sci.*, 2006, **71**, C430–C436.
- 32 A. K. Sachdeva, S. Misra, I. P. Kaur and K. Chopra, Neuroprotective potential of sesamol and its loaded solid lipid nanoparticles in ICV-STZ-induced cognitive deficits: behavioral and biochemical evidence, *Eur. J. Pharmacol.*, 2015, **747**, 132–140.
- 33 P. Jayaraj, C. A. Narasimhulu, S. Rajagopalan, S. Parthasarathy and R. Desikan, Sesamol: a powerful functional food ingredient from sesame oil for cardioprotection, *Food Funct.*, 2020, **11**, 1198–1210.
- 34 T. Geetha, P. K. Deol and I. P. Kaur, Role of sesamol-loaded floating beads in gastric cancers: a pharmacokinetic and biochemical evidence, *J. Microencapsulation*, 2015, **32**, 478–487.
- 35 G. J. Kapadia, M. A. Azuine, H. Tokuda, M. Takasaki, T. Mukainaka, T. Konoshima and H. Nishino, Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis, *Pharmacol. Res.*, 2002, **45**, 499–505.
- 36 P. Y. Chu, D. Z. Hsu, P. Y. Hsu and M. Y. Liu, Sesamol down-regulates the lipopolysaccharide-induced inflammatory response by inhibiting nuclear factor-kappa B activation, *Innate Immun.*, 2010, **16**, 333–339.
- 37 V. K. Parihar, K. R. Prabhakar, V. P. Veerapur, M. S. Kumar, Y. R. Reddy, R. Joshi, M. K. Unnikrishnan and C. M. Rao, Effect of sesamol on radiation-induced cytotoxicity in Swiss albino mice, *Mutat. Res., Genet. Toxicol. Environ. Mutagen.*, 2006, **611**, 9–16.
- 38 M. Srisayam, N. Weerapreeyakul, S. Barusrux and K. Kanokmedhakul, Antioxidant, antimelanogenic, and skin-protective effect of sesamol, *J. Cosmet. Sci.*, 2014, **65**, 69–79.
- 39 K. C. Jan, C. T. Ho and L. S. Hwang, Bioavailability and tissue distribution of sesamol in rat, *J. Agric. Food Chem.*, 2008, **56**, 7032–7037.
- 40 K. C. Jan, C. T. Ho and L. S. Hwang, Elimination and metabolism of sesamol, a bioactive compound in sesame oil, in rats, *Mol. Nutr. Food Res.*, 2009, **53**, 36–43.
- 41 C. D. Klaassen and J. Y. Cui, Mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids, *Drug Metab. Dispos.*, 2015, **43**, 1505–1521.
- 42 X. Yang, R. Hu, L. Yao, W. Zhang, M. Shi, J. Gong, X. Yuan, Y. Li, J. Yan, Y. Wang, Q. Zhang, Z. He, D.-X. Hou, Z. Fan, H. Zhang, L. Chen, X. He, J. He and S. Wu, The role of uterus mitochondrial function in high-fat diet-related adverse pregnancy outcomes and protection by resveratrol, *Food Funct.*, 2024, **15**, 4852–4861.
- 43 M. Andargie, M. Vinas, A. Rathgeb, E. Möller and P. Karlovsky, Lignans of sesame (*Sesamum indicum* L.): A comprehensive review, *Molecules*, 2021, **26**, 883.
- 44 K. Yamashita, Y. Yamada, S. Kitou, S. Ikeda, C. Abe, N. M. Saarinen and R. Santti, Hydroxymatairesinol and sesaminol act differently on tocopherol concentrations in rats, *J. Nutr. Sci. Vitaminol.*, 2007, **53**, 393–399.
- 45 A. Santini, G. C. Tenore and E. Novellino, Nutraceuticals: a paradigm of proactive medicine, *Eur. J. Pharm. Sci.*, 2017, **96**, 53–61.
- 46 B. Wilffert, J. Swen, H. Mulder, D. Touw, A.-H. M. Van der Zee and V. Deneer, From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics, *Int. J. Clin. Pharm.*, 2013, **35**, 369–375.

